Avirmax , Inc. is dedicated to innovate, develop and manufacture adeno-associated virus (AAV) vector mediated biotherapeutics using its proprietary protein therapeutics and Bac-to-AAV (a VP1 enriched AAV production with baculovirus helpers in Sf9 cells) technologies. Our team of experts have worked extensively to innovate and develop AAV vectors and optimize recombinant vector production, purification and scale-up manufacturing. Using the advanced Bac-to-AAV system, allows Avirmax to quickly deliver quality cGMP material to our clients.